Annual Report for the year ended 30 June 2023

MGC Pharmaceuticals Limited
29 September 2023
 

 

MGC Pharmaceuticals Ltd.

Annual Report for the year ended 30 June 2023

and ASX Corporate Governance Statement

29 September 2023

ASX, LSE: MXC

 

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') is pleased to provide the following documents in respect of the financial year ended 30 June 2023:

·      Annual Financial Report (Audited)

A copy of the Company's Annual Financial Report for the year ended 30 June 2023 can be found at the following URL:
https://www.investi.com.au/api/announcements/mxc/afa2a099-b57.pdf

·      ASX Appendix 4G "Key disclosures - Corporate Governance Council Principles and Recommendations" and MGC Pharma's Corporate Governance Statement

A copy of the Company's ASX Appendix 4G - Corporate Governance Disclosures & Corporate Governance Statement can be found at the following URL:

https://www.investi.com.au/api/announcements/mxc/7516e7d4-208.pdf

 

-Ends-

 

Authorised for release by the Managing Director, for further information please contact:

MGC Pharmaceuticals Ltd     

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

info@mgcpharma.co.uk

MGC Pharmaceuticals Ltd

Rowan Harland

Company Secretary

+61 8 6555 2950

info@mgcpharma.co.uk

UK IR/PR Advisers 

IFC Advisory

Graham Herring / Tim Metcalfe / Zach Cohen

+44 203 934 6630

mgcpharma@investor-focus.co.uk

UK Brokers

Oberon Capital

Aimee McCusker / Adam Pollock

+44 203 179 5300

aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com 

 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant derived medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

 

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.

 

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development. 

 

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant derived medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities. 

 

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings